Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 15.1% Higher

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPHGet Rating) (TSE:AUP) traded up 15.1% during trading on Thursday . The company traded as high as $9.82 and last traded at $9.78. 76,650 shares changed hands during trading, a decline of 97% from the average session volume of 2,629,236 shares. The stock had previously closed at $8.50.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Royal Bank of Canada lowered their target price on shares of Aurinia Pharmaceuticals from $22.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, April 28th. StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 23rd. Finally, HC Wainwright decreased their price objective on shares of Aurinia Pharmaceuticals from $33.00 to $30.00 in a research note on Wednesday, May 4th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $24.80.

Aurinia Pharmaceuticals Trading Down 1.8 %

The stock’s 50 day moving average price is $10.63 and its 200 day moving average price is $12.25. The firm has a market cap of $1.19 billion, a PE ratio of -7.22 and a beta of 0.94.

Aurinia Pharmaceuticals (NASDAQ:AUPHGet Rating) (TSE:AUP) last released its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.03). Aurinia Pharmaceuticals had a negative return on equity of 38.37% and a negative net margin of 178.32%. During the same quarter in the previous year, the company posted ($0.37) EPS. Analysts forecast that Aurinia Pharmaceuticals Inc. will post -0.7 earnings per share for the current year.

Institutional Trading of Aurinia Pharmaceuticals

Several hedge funds have recently bought and sold shares of AUPH. Lazard Asset Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter worth about $45,000. Tcwp LLC purchased a new position in shares of Aurinia Pharmaceuticals in the first quarter worth approximately $25,000. Total Clarity Wealth Management Inc. purchased a new position in Aurinia Pharmaceuticals during the second quarter valued at approximately $26,000. Geneos Wealth Management Inc. grew its position in Aurinia Pharmaceuticals by 54.2% during the first quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 1,142 shares in the last quarter. Finally, Nisa Investment Advisors LLC bought a new stake in Aurinia Pharmaceuticals in the second quarter worth approximately $34,000. 33.09% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

See Also

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.